| Literature DB >> 28708126 |
Krzysztof Durkalec-Michalski1,2, Jan Jeszka3, Tomasz Podgórski4.
Abstract
The aim of this study was to verify the effect of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on physical capacity, body composition and the value of biochemical parameters in highly-trained combat sports athletes. Forty-two males highly-trained in combat sports were subjected to 12 weeks of supplementation with HMB and a placebo in a randomized, placebo controlled, double-blind crossover manner. Over the course of the experiment, aerobic and anaerobic capacity was determined, while analyses were conducted on body composition and levels of creatine kinase, lactate dehydrogenase, testosterone, cortisol and lactate. Following HMB supplementation, fat-free mass increased (p = 0.049) with a simultaneous reduction of fat mass (p = 0.016) in comparison to placebo. In turn, after HMB supplementation, the following indicators increased significantly in comparison to the placebo: the time to reach ventilatory threshold (p < 0.0001), threshold load (p = 0.017) and the threshold HR (p < 0.0001), as well as anaerobic peak power (p = 0.005), average power (p = 0.029), maximum speed (p < 0.001) and post-exercise lactate concentrations (p < 0.0001). However, when compared to the placebo, no differences were observed in blood marker levels. The results indicate that supplying HMB promotes advantageous changes in body composition and stimulates an increase in aerobic and anaerobic capacity in combat sports athletes.Entities:
Keywords: adaptation; body composition; maximal oxygen uptake; muscle power indices; sport; supplements; training support; β-hydroxy-β-methylbutyric acid
Mesh:
Substances:
Year: 2017 PMID: 28708126 PMCID: PMC5537867 DOI: 10.3390/nu9070753
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1A flow chart of the study design. Abbreviations: BJJ, Brazilian jiu-jitsu; HMB, β-hydroxy-β-methylbutyric acid; PLA, placebo.
Characteristics of the participating athletes (N = 42 subjects).
| Variable | Unit | HMB | PLA | |
|---|---|---|---|---|
| Age | (year) | 22.8 ± 6.1 | ||
| Body mass | (kg) | 81.2 ± 12.8 | ||
| Height | (cm) | 179 ± 6 | ||
| Years training | (year) | 7.5 ± 3.6 | ||
| Energy intake * | kcal | 3081 ± 841 | 3141 ± 789 | 0.2965 |
| (kcal/kg/day) | 37.7 ± 6.5 | 38.4 ± 5.6 | 0.1800 | |
| Protein intake * | g | 141 ± 40 | 145 ± 44 | 0.1054 |
| (g/kg/day) | 1.7 ± 0.3 | 1.8 ± 0.3 | 0.1181 | |
| % | 18.5 ± 3.5 | 18.6 ± 3.3 | 0.8175 | |
| Carbohydrate intake * | g | 359 ± 112 | 374 ± 97 | 0.1683 |
| (g/kg/day) | 4.4 ± 1.0 | 4.6 ± 0.8 | 0.0938 | |
| % | 46.6 ± 6.6 | 47.7 ± 5.2 | 0.1535 | |
| Fat intake * | g | 120 ± 44 | 118 ± 41 | 0.3202 |
| (g/kg/day) | 1.5 ± 0.4 | 1.4 ± 0.4 | 0.2135 | |
| % | 34.9 ± 7.2 | 33.7 ± 6.2 | 0.1109 | |
| Combat sports training * | (session/week) | 5.2 ± 1.4 | 5.2 ± 1.3 | 0.8446 |
| Supporting endurance training (running, cycling and other) * | (session/week) | 1.3 ± 0.9 | 1.4 ± 0.8 | 0.3942 |
| Supporting strength and power training * | (session/week) | 1.9 ± 0.8 | 1.8 ± 0.7 | 0.4080 |
| The total amount of all trainings * | (session/week) | 8.3 ± 2.3 | 8.3 ± 2.1 | 0.8734 |
Values are means ± SD. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; PLA, placebo. * Data registered during the supplementation period. a Depending on the data distribution: dependent samples t-tests or Wilcoxon-signed rank tests.
Figure 2Changes in body composition after 12-week supplementation of HMB and placebo. Values are means ± SD and 95% CI. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; FFM, fat-free mass; FM, fat mass. Significant differences compared with placebo: * p = 0.049 (dependent samples t-tests), ** p = 0.016 (dependent samples t-tests).
Body mass and body composition indices before and after the 12-week supplementation with HMB and placebo preparation.
| Parameter | PRE: HMB vs. PLA | HMB | HMB: Pre vs. Post | PLACEBO | PLA: Pre vs. Post | POST: HMB vs. PLA | SO (HMB➔PLA vs. PLA➔HMB) | |
|---|---|---|---|---|---|---|---|---|
| Body composition indices | ||||||||
| Body mass (kg) | Pre | 0.978 | 81.1 ± 12.7 | 0.905 | 81.0 ± 12.6 | 0.627 | 0.936 | 0.690 |
| Post | 81.0 ± 12.2 | 81.2 ± 12.1 | ||||||
| TBW (L) | Pre | 0.821 | 49.6 ± 6.1 | 0.079 | 49.9 ± 6.2 | 0.208 | 0.626 | 0.938 |
| Post | 50.1 ± 5.8 | 49.5 ± 5.9 | ||||||
| FFM (kg) | Pre | 0.817 | 67.7 ± 8.4 | 0.071 | 68.1 ± 8.4 | 0.146 | 0.599 | 0.937 |
| Post | 68.5 ± 8.0 | 67.6 ± 8.0 | ||||||
| FFM (%) | Pre | 0.558 | 84.0 ± 4.6 | 84.6 ± 5.0 | 0.213 | 0.146 | ||
| Post | 85.0 ± 5.1 | 83.7 ± 4.6 | ||||||
| FM (kg) | Pre | 0.639 | 13.4 ± 5.5 | 12.9 ± 5.8 | 0.334 | 0.317 | ||
| Post | 12.6 ± 5.7 | 13.6 ± 5.4 | ||||||
| FM (%) | Pre | 0.568 | 16.0 ± 4.6 | 15.4 ± 5.0 | 0.224 | 0.153 | ||
| Post | 15.0 ± 5.0 | 16.3 ± 4.5 | ||||||
Values are means ± SD. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; PLA, placebo, SO, supplementation order (HMB➔PLA vs. PLA➔HMB); TBW, total body water content; FFM, fat-free mass; FM, fat mass. a Depending on the data distribution: independent samples t-tests or Mann–Whitney U tests; b Depending on the data distribution: Dependent samples t-tests or Wilcoxon-signed rank tests; c ANOVA for repeated measurement.
Figure 3Changes in rates at ventilatory threshold after 12-week supplementation of HMB and placebo. Values are means ± SD and 95% CI. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; VT, ventilatory threshold; TVT, time to VT; WVT, load at VT; HRVT, heart rate at VT. Significant differences compared with placebo: * p < 0.0001 (dependent samples t-tests); # p = 0.017 (Wilcoxon rank-sum test); † p < 0.0001 (dependent samples t-tests).
Levels of the monitored aerobic capacity indices before and after the 12-week supplementation with HMB and placebo preparation.
| Parameter | PRE: HMB vs. PLA | HMB | HMB: Pre vs. Post | PLACEBO | PLA: Pre vs. Post | POST: HMB vs. PLA | SO (HMB➔PLA vs. PLA➔HMB) | |
|---|---|---|---|---|---|---|---|---|
| Pre | 0.596 | 57.3 ± 7.3 | 0.083 | 58.2 ± 7.5 | 0.455 | 0.498 | 0.724 | |
| Post | 58.6 ± 6.1 | 57.7 ± 6.8 | ||||||
| Pre | 0.598 | 4603 ± 624 | 0.115 | 4663 ± 625 | 0.537 | 0.523 | 0.350 | |
| Post | 4709 ± 591 | 4627 ± 581 | ||||||
| Tref (s) | Pre | 0.623 | 719 ± 114 | 746 ± 139 | 0.851 | 0.567 | 0.085 | |
| Post | 753 ± 140 | 751 ± 171 | ||||||
| Wmax (W) | Pre | 0.452 | 281 ± 33 | 290 ± 42 | 0.856 | 0.870 | 0.060 | |
| Post | 294 ± 42 | 292 ± 48 | ||||||
| Wmax (W/kg) | Pre | 0.326 | 3.5 ± 0.5 | 0.051 | 3.6 ± 0.5 | 0.951 | 0.971 | 0.293 |
| Post | 3.7 ± 0.5 | 3.6 ± 0.6 | ||||||
| HRmax (bpm) | Pre | 0.459 | 181 ± 9 | 182 ± 10 | 0.325 | 0.922 | 0.129 | |
| Post | 183 ± 10 | 183 ± 10 | ||||||
| TVT (s) | Pre | 0.074 | 505 ± 91 | 543 ± 100 | 0.080 | |||
| Post | 564 ± 89 | 518 ± 105 | ||||||
| WVT (W) | Pre | 0.206 | 220 ± 29 | 231 ± 29 | 0.221 | 0.112 | 0.181 | |
| Post | 236 ± 28 | 225 ± 34 | ||||||
| WVT (W/kg) | Pre | 0.111 | 2.7 ± 0.4 | 2.9 ± 0.4 | 0.098 | 0.202 | 0.625 | |
| Post | 2.9 ± 0.4 | 2.8 ± 0.4 | ||||||
| HRVT (bpm) | Pre | 0.055 | 158 ± 10 | 163 ± 12 | 0.105 | 0.069 | 0.111 | |
| Post | 165 ± 11 | 161 ± 11 | ||||||
| Post | 13.1 ± 1.7 | 12.1 ± 1.4 |
Values are means ± SD. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; PLA, placebo; SO, supplementation order (HMB➔PLA vs. PLA➔HMB); O2max, maximal oxygen uptake; Tref, exercise time before athlete’s refusal to continue exercising; Wmax, maximum load; HRmax, maximum heart rate; VT, ventilatory threshold; TVT, time to VT; WVT, load at VT; HRVT, heart rate at VT. a Depending on the data distribution: independent samples t-tests or Mann–Whitney U tests; b Depending on the data distribution: dependent samples t-tests or Wilcoxon-signed rank tests; c ANOVA for repeated measurement.
Levels of the monitored selected biochemical markers before and after the 12-week supplementation with HMB and placebo preparation.
| Parameter | PRE: HMB vs. PLA | HMB | HMB: Pre vs. Post | PLACEBO | PLA: Pre vs. Post | POST: HMB vs. PLA | SO (HMB➔PLA vs. PLA➔HMB) | |
|---|---|---|---|---|---|---|---|---|
| CK (U/L) | Pre | 0.737 | 310 ± 275 | 0.778 | 268 ± 165 | 0.198 | 0.400 | 0.591 |
| Post | 302 ± 226 | 258 ± 194 | ||||||
| LDH (U/L) | Pre | 0.817 | 320 ± 57 | 0.903 | 323 ± 61 | 0.114 | 0.721 | |
| Post | 321 ± 63 | 301 ± 53 | ||||||
| Testosterone (nmol/L) | Pre | 0.940 | 16.5 ± 5.4 | 0.053 | 16.5 ± 4.4 | 0.336 | 0.403 | 0.116 |
| Post | 18.5 ± 7.9 | 17.1 ± 4.4 | ||||||
| Cortisol (nmol/L) | Pre | 0.895 | 499 ± 154 | 0.063 | 495 ± 160 | 0.900 | 0.968 | |
| Post | 545 ± 170 | 552 ± 168 | ||||||
| T/C ratio (T/C·10) | Pre | 0.546 | 3.68 ± 1.94 | 0.886 | 3.75 ± 1.81 | 0.138 | 0.567 | 0.232 |
| Post | 3.68 ± 1.88 | 3.37 ± 1.30 | ||||||
| Lactate (mmol/L) | Pre | 0.886 | 1.7 ± 0.6 | 0.180 | 1.7 ± 0.7 | 0.282 | 0.854 | 0.350 |
| Post | 2.0 ± 1.1 | 1.9 ± 0.8 |
Values are means ± SD. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; PLA, placebo; SO, supplementation order (HMB➔PLA vs. PLA➔HMB); CK, creatine kinase; LDH, lactate dehydrogenase; T/C ratio, testosterone/cortisol ratio. a Depending on the data distribution: independent samples t-tests or Mann–Whitney U tests; b Depending on the data distribution: dependent samples t-tests or Wilcoxon-signed rank tests; c ANOVA for repeated measurement.
Figure 4Changes in the anaerobic capacity after 12-week supplementation of HMB and placebo. Values are means ± SD and 95% CI. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; LAPOST, post-exercise lactate concentrations. Significant differences compared with placebo: * p = 0.005 (dependent samples t-tests); # p = 0.029 (dependent samples t-tests); † p < 0.001 (dependent samples t-tests). ‡ p < 0.0001 (dependent samples t-tests).
Levels of the monitored anaerobic capacity parameters before and after the 12-week supplementation with HMB and placebo preparation.
| Parameter | PRE: HMB vs. PLA | HMB | HMB: Pre vs. Post | PLACEBO | PLA: Pre vs. Post | POST: HMB vs. PLA | SO (HMB➔PLA vs. PLA➔HMB) | |
|---|---|---|---|---|---|---|---|---|
| Peak Power (W) | Pre | 0.511 | 901 ± 197 | 930 ± 208 | 0.240 | 0.251 | 0.468 | |
| Post | 998 ± 197 | 949 ± 184 | ||||||
| Peak Power (W/kg) | Pre | 0.312 | 11.1 ± 1.6 | 11.5 ± 1.7 | 0.236 | 0.692 | ||
| Post | 12.3 ± 1.6 | 11.7 ± 1.6 | ||||||
| Time at PP (s) | Pre | 0.761 | 2.98 ± 2.01 | 2.71 ± 1.49 | 0.975 | 0.301 | 0.826 | |
| Post | 2.36 ± 1.06 | 2.67 ± 1.34 | ||||||
| Average Power (W) | Pre | 0.618 | 628 ± 109 | 640 ± 117 | 0.910 | 0.597 | 0.529 | |
| Post | 653 ± 108 | 641 ± 99 | ||||||
| Average Power (W/kg) | Pre | 0.307 | 7.7 ± 0.7 | 7.9 ± 0.7 | 0.811 | 0.265 | 0.865 | |
| Post | 8.1 ± 0.6 | 7.9 ± 0.6 | ||||||
| Minimal Power (W) | Pre | 0.758 | 379 ± 70 | 0.581 | 374 ± 78 | 0.435 | 0.917 | 0.614 |
| Post | 385 ± 65 | 383 ± 61 | ||||||
| Minimal Power (W/kg) | Pre | 0.591 | 4.7 ± 0.7 | 0.604 | 4.7 ± 0.9 | 0.846 | 0.822 | 0.813 |
| Post | 4.8 ± 0.6 | 4.7 ± 0.6 | ||||||
| Max speed (rpm) | Pre | 0.265 | 129 ± 14 | 132 ± 15 | 0.803 | 0.083 | 0.474 | |
| Post | 138 ± 13 | 133 ± 13 | ||||||
| LactatePRE (mmol/L) | Pre | 0.664 | 1.6 ± 0.4 | 0.346 | 1.6 ± 0.5 | 0.153 | 0.851 | 0.150 |
| Post | 1.5 ± 0.5 | 1.5 ± 0.6 | ||||||
| LactatePOST (mmol/L) | Pre | 0.078 | 11.6 ± 1.7 | 12.2 ± 1.6 | 0.482 | 0.978 | ||
| Post | 13.1 ± 1.7 | 12.1 ± 1.4 |
Values are means ± SD. Abbreviations: HMB, β-hydroxy-β-methylbutyric acid; PLA, placebo; SO, supplementation order (HMB➔PLA vs. PLA➔HMB). a Depending on the data distribution: independent samples t-tests or Mann–Whitney U tests; b Depending on the data distribution: Dependent samples t-tests or Wilcoxon-signed rank tests; c ANOVA for repeated measurement.